Staff at EMBL

Dr. Joe Lewis

Head of Chemical Biology Core Facility
Chemical Biology Core Facility

EMBL Heidelberg, Meyerhofstraße 1, 69117 Heidelberg, Germany

Biography

PhD 1991, Institute of Molecular Pathology, Vienna.
Postdoctoral research at EMBL.
Group and Global HCV project leader at Anadys Pharmaceuticals, Heidelberg.
MBA 2008, Mannheim Business School.
Facility head at EMBL since 2004.

Publications

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Hose, D., Reme, T., Meissner, T., Moreaux, J., Seckinger, A., Lewis, J.D., Benes, V., Benner, A., Hundemer, M., Hielscher, T., Shaughnessy JD, J.r, Barlogie, B., Neben, K., Kramer, A., Hillengass, J., Bertsch, U., Jauch, A., De Vos, J., Rossi, J.F., Mohler, T., Blake, J., Zimmermann, J., Klein, B. & Goldschmidt, H. Blood. 2009 Apr 30;113(18):4331-40. Epub 2009 Jan 26. PubMed

Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. Bartonova, V., Igonet, S., Sticht, J., Glass, B., Habermann, A., Vaney, M.C., Sehr, P., Lewis, J.D., Rey, F.A. & Krausslich, H.G. J Biol Chem. 2008 Nov 14;283(46):32024-33. Epub 2008 Sep 4. PubMed

The structural basis for cap binding by influenza virus polymerase subunit PB2. Guilligay, D., Tarendeau, F., Resa-Infante, P., Coloma, R., Crepin, T., Sehr, P., Lewis, J.D., Ruigrok, R.W., Ortin, J., Hart, D.J. & Cusack, S. Nat Struct Mol Biol. 2008 May;15(5):500-6. Epub 2008 May 4. PubMed

The E6 oncoprotein of human papillomavirus 16 as a therapeutic target Dymalla, S; Butz, K; Lohrey, C; Scheffner, M; Sehr, P; Lewis, J; Hoppe-Seyler, F Molecular Cancer Therapeutics Dec 2007 6(12)

Evaluation of different glutathione S-transferase-tagged protein captures for screening E6/E6AP interaction inhibitors using AlphaScreen. Sehr, P., Pawlita, M. & Lewis, J. J Biomol Screen. 2007 Jun;12(4):560-7. Epub 2007 May 3. PubMed

Thanatop: a novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase II. Polycarpou-Schwarz, M., Muller, K., Denger, S., Riddell, A., Lewis, J.D., Gannon, F. & Reid, G. Cancer Res. 2007 May 1;67(9):4451-8. PubMed

The role of the chemical biology core facility at EMBL: a vision for a European roadmap. Lewis, J.D. ACS Chem Biol. 2007 Jan 23;2(1):21-3. PubMed

Systematic discovery of new recognition peptides mediating protein interaction networks. Neduva, V., Linding, R., Su-Angrand, I., Stark, A., de Masi, F., Gibson, T.J., Lewis, J.D., Serrano, L. & Russell, R.B. PLoS Biol. 2005 Dec;3(12):e405. Epub 2005 Nov 15. PubMed

The role of RNA interference in drug target validation: Application to Hepatitis C. Ostareck-Lederer, A., Clauder-Münster, S., Thermann, R., Polycarpou-Schwartz, M., Gentzel, M., Wilm, M. & Lewis, J.D. In "RNA Interference Technology", Appasani, K. (ed.), 2005, Cambridge University Press, pp. 318-330

Structure of the hepatitis C virus IRES bound to the human 80S ribosome: Remodelling of the HCV IHRES. Boehringer, D., Thermann, R., Ostareck-Lederer, A., Lewis, J.D. & Stark, H. Structure 2005 13(11) 1695-1706